AMOEBA (EPA:ALMIB) - Amoeba announces the results of a safety & efficacy study assessing the fate of Legionella pneumophila in Willaertia magna C2c Maky.

Transparency directive : regulatory news

07/11/2018 17:40

PRESS RELEASE

AMOEBA announces the results of a safety & efficacy study assessing the fate of
Legionella pneumophila in Willaertia magna C2c Maky.

Lyon (France), November 7, 2018 - AMOEBA (FR0011051598 - AMEBA), producer of a
biological biocide capable of eliminating bacterial risk in water, plant
protection and wound care applications, announces the results of a laboratory
safety & efficacy study.

The objectives of the study were to assess the fate of Legionella pneumophila
when internalized in the free-living amoebae Willaertia magna C2c Maky (the
biocidal active substance) and to compare the results with two other
free-living amoebae behavior.

Briefly, the clinical strain Legionella pneumophila Philadelphia (ATCC(r)
33152(tm)) and Willaertia magna C2c Maky (ATCC(r) PTA-7824) were put in contact
at the same ratio during two hours to allow the internalization of Legionella
within Willaertia magna C2c Maky (process of phagocytosis). Then, the internal
Legionella level was monitored during 4 days using the gold-standard method of
culture.

In parallel, the same protocol was performed using Willaertia magna Z503
(ATCC(r) 50035(tm)) and Acanthamoeba castellanii (Douglas) Page (ATCC(r) 30010)
as positive controls, as those two other free- living amoebae are known to
multiply Legionella pneumophila and strongly represented in cooling towers.

Each condition was performed in duplicate and was repeated at least 3 times
over time.

The following figure present the evolution of internal Legionella level over
the 4 days, monitored in the three free-living amoebae:

The study results demonstrate, in the experimental conditions:

- A strong efficacy of Willaertia magna C2c Maky to eliminate the Legionella:
  at least 90% Legionella are destroyed within 24 hours and more than 99,9%
  within 72 hours.

- After 4 days, a complete absence of culturable bacteria in Willaertia magna
  C2c Maky infected with Legionella, showing the absence of legionella
  survival.

- An absence of Legionella multiplication in Willaertia magna C2c Maky, at any
  time.

- On the contrary, a multiplication of Legionella in Willaertia magna Z503 and
  in Acanthamoeba castellanii results in accordance with published scientific
  literature *.

These study results hence demonstrate that, in experimental conditions, any
Legionella pneumophila Philadelphia ingested by Willaertia magna C2c Maky will
in fine be digested. This digestion proceeds without any multiplication nor
survival of the pathogenic bacteria within the amoeba.

* Refer to Holden et al. (1984). Intracellular growth of Legionella pneumophila
within Acanthamoeba castellanii Neff. Infect. Immun. 45, 18-24. Refer to Dey et
al. (2009). Free-living freshwater amoebae differ in their susceptibility to
the pathogenic bacterium Legionella pneumophila. FEMS Microbiol Lett 290,
10-17.

"This study required more than 3 months of works to validate the laboratory
conditions, the purification methods and the reaction media to be used. The
results of this study complement our knowledge on Willaertia magna C2c Maky and
demonstrate not only the efficacy of the active substance, destroying the
Legionella, but also a safety aspect of the substance with the absence of
Legionella multiplication and survival. This absence of survival and
multiplication is to be put in perspective with other amoebae behavior like
Acanthamoeba castellanii that are widely found in cooling towers and multiply
the Legionella." declares Fabrice PLASSON, Chairman of AMOEBA.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. Created in 2010, based in Chassieu (Lyon, France) with a
subsidiary in Canada and in the United States, Amoéba is quoted on the
compartment C of Euronext Paris. The Company is a member of the BPIfrance
Excellence network and is eligible for the PEA-PME SME equity savings plan
setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets (3): BCC Research, "Markets for Advanced Wound Management
Technologies," Wellesley, MA, 2017 (4): Biopesticides Worldwide Market 2013,
CPL, Wallingford, UK

Contacts :

Amoéba
Valérie FILIATRE
Directeur administratif et Financier
04 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Communication financière
01 56 88 11 11
ggasparetto@actifin.fr

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 27, 2018 (a copy of which is available on
www.amoeba-biocide.com). The forward-looking statements contained in this press
release are also subject to risks not yet known to AMOEBA or not currently
considered material by AMOEBA. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or achievements
of AMOEBA to be materially different from such forward-looking statements.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - Amoeba announces the results of a safety & efficacy study assessing the fate of Legionella pneumophila in Willaertia magna C2c Maky.

Transparency directive : regulatory news

AMOEBA's latest news

Other stories